DK1565196T3 - Fremgangsmåde til fremstilling af dendritceller til cancerterapi - Google Patents

Fremgangsmåde til fremstilling af dendritceller til cancerterapi

Info

Publication number
DK1565196T3
DK1565196T3 DK03774329T DK03774329T DK1565196T3 DK 1565196 T3 DK1565196 T3 DK 1565196T3 DK 03774329 T DK03774329 T DK 03774329T DK 03774329 T DK03774329 T DK 03774329T DK 1565196 T3 DK1565196 T3 DK 1565196T3
Authority
DK
Denmark
Prior art keywords
dendritic cell
preparation
dendritic cells
cancer therapy
cancer
Prior art date
Application number
DK03774329T
Other languages
Danish (da)
English (en)
Inventor
Chi-Dug Kang
Min-Ho Jeong
Original Assignee
Lee Baek Chung
Binex Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lee Baek Chung, Binex Co Ltd filed Critical Lee Baek Chung
Application granted granted Critical
Publication of DK1565196T3 publication Critical patent/DK1565196T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK03774329T 2002-11-28 2003-11-26 Fremgangsmåde til fremstilling af dendritceller til cancerterapi DK1565196T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2002-0074834A KR100522526B1 (ko) 2002-11-28 2002-11-28 면역 치료용 수지상 세포의 제조방법
PCT/KR2003/002572 WO2004047849A1 (fr) 2002-11-28 2003-11-26 Application clinique d'immunotherapie anticancereuse reposant sur une cellule dendritique

Publications (1)

Publication Number Publication Date
DK1565196T3 true DK1565196T3 (da) 2007-11-05

Family

ID=36165395

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03774329T DK1565196T3 (da) 2002-11-28 2003-11-26 Fremgangsmåde til fremstilling af dendritceller til cancerterapi

Country Status (12)

Country Link
US (1) US20050008622A1 (fr)
EP (1) EP1565196B1 (fr)
JP (1) JP2006509002A (fr)
KR (1) KR100522526B1 (fr)
CN (1) CN100406555C (fr)
AT (1) ATE373481T1 (fr)
AU (1) AU2003282438A1 (fr)
CA (1) CA2474066A1 (fr)
DE (1) DE60316463T2 (fr)
DK (1) DK1565196T3 (fr)
ES (1) ES2293046T3 (fr)
WO (1) WO2004047849A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101450497B1 (ko) 2004-09-14 2014-10-13 아고스 쎄라퓨틱스, 인코포레이티드 병원체의 균주 독립성 증폭 및 그에 대한 백신

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
EP0563485A1 (fr) * 1992-03-30 1993-10-06 Schering-Plough Génération in vitro de cellules dendritiques humaines et leurs usages
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
EA199800272A1 (ru) * 1995-10-04 1998-10-29 Иммунекс Корпорейшн Фактор, стимулирующий дендритные клетки
KR20020013470A (ko) * 1998-10-02 2002-02-20 미우라 아키라 세포성 면역의 유도방법 및 세포성 면역이 유도된 세포
KR100868235B1 (ko) * 1999-11-15 2008-11-12 밀테니 비오텍 게앰베하 수지상 세포에 특이적인 항원-결합 단편, 단편을 사용한조성물 및 방법, 그것에 의해 인식된 항원, 및 그것에의해 얻어진 세포
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
GB0111015D0 (en) * 2001-05-04 2001-06-27 Norsk Hydro As Genetic material

Also Published As

Publication number Publication date
CN1705489A (zh) 2005-12-07
WO2004047849A1 (fr) 2004-06-10
ES2293046T3 (es) 2008-03-16
DE60316463D1 (de) 2007-10-31
US20050008622A1 (en) 2005-01-13
CN100406555C (zh) 2008-07-30
ATE373481T1 (de) 2007-10-15
CA2474066A1 (fr) 2004-06-10
KR100522526B1 (ko) 2005-10-19
EP1565196B1 (fr) 2007-09-19
AU2003282438A8 (en) 2004-06-18
AU2003282438A1 (en) 2004-06-18
EP1565196A4 (fr) 2006-03-15
DE60316463T2 (de) 2008-06-26
EP1565196A1 (fr) 2005-08-24
JP2006509002A (ja) 2006-03-16
KR20040046804A (ko) 2004-06-05

Similar Documents

Publication Publication Date Title
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
DK1629088T3 (da) Varianter af prostatastamcelleantigen (psca) og undersekvenser deraf
TW200513280A (en) Microprojection array immunization patch and method
IL96893A0 (en) Vaccines against cancer and infectious diseases
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
IL141868A0 (en) Novel methods for therapeutic vaccination
MXPA03001634A (es) Polipeptido tumoral cripto.
PL371685A1 (en) Fused cyclic modulators of nuclear hormone receptor function
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
AU2002364082A1 (en) Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
ATE391726T1 (de) Modifiziertes gp100 und dessen verwendung
MX2022002578A (es) Inmunoterapia dirigida a peptidos neoantigenicos tumorales.
DE69722937D1 (de) Bor-neutronen-einfangtherapie unter verwendung von pre-targeting-methoden
WO2003033520A3 (fr) Vaccin anticancereux, methodes diagnostiques et reactifs
DE60334382D1 (de) Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
DK1565196T3 (da) Fremgangsmåde til fremstilling af dendritceller til cancerterapi
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
WO2001057207A3 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação
EP0684831A4 (fr) Vaccin allogene et procede de synthese de ce vaccin.
WO2002045657A3 (fr) Antigene de la tumeur de l'ovaire et ses utilisations